Ratings by Lucid Capital Markets
| Date | Analyst | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|---|
| 3/2/2026 | Christopher Liu | Relmada Therapeutics Inc | RLMD | New Coverage | Buy (N/A) |
14.00 (N/A) |
4.56 (4.45) |
-2.41% | Details |
| 2/24/2026 | Dev Prasad | Palvella Therapeutics | PVLA | Maintain | Buy (N/A) |
241.00 (212.00) |
|
Details | |
 |
|||||||||
|
|||||||||
|
|||||||||
|
|||||||||
|
|||||||||
|
|||||||||
|
|||||||||
|
|||||||||
| 130 more... | |||||||||
